Literature DB >> 9176522

Heterologous expression of adenovirus E3-gp19K in an E1a-deleted adenovirus vector inhibits MHC I expression in vitro, but does not prolong transgene expression in vivo.

D B Schowalter1, J C Tubb, M Liu, C B Wilson, M A Kay.   

Abstract

An E1a-deleted adenovirus vector constitutively expressing native adenovirus E3-gp19K (Ad.RSV-gp19K) was constructed in order to determine whether or not E3-gp19K mediated interference with antigen presentation would result in prolonged transgene expression in vivo. Cultured fibroblasts infected with Ad.RSV-gp19K produced a native size gp19K protein and had decreased cell surface levels of MHC I as shown by immunoprecipitation and flow cytometry. The congenic mouse strains Balb/b (H-2b MHC I with high gp19K affinity), Balb/k (H-2k MHC I with no gp19K affinity), and Balb/c (H-2d MHC I with moderate gp19K affinity) were chosen for in vivo experiments because of their range of gp19K affinities. Following transduction of mice form each strain with Ad.RSV-gp19K and AD/RSV-hAAT (a reporter adenovirus), or Ad/RSV-cFIX (control adenovirus) and Ad/RSV-hAAT, the level and duration of serum hAAT protein were unrelated to gp19K protein expression. Evaluation of MHC I abundance on hepatocytes following in vivo transduction demonstrated that recombinant adenovirus rapidly increased the abundance of surface MHC I molecules on hepatocytes, and surface MHC I molecules were reduced earlier and to a greater extent following wild-type adenovirus infection compared with hepatocytes transduced with control or Ad.RSV-gp19K recombinant adenovirus. This difference in surface MHC I down-regulation may be related to the different promoters (RSV-LTR versus the native E3 promoter) and will be an important consideration in the development of newer generation adenovirus vectors designed to evade host immune responses.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9176522     DOI: 10.1038/sj.gt.3300398

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  8 in total

1.  Nonmyeloablative immunosuppressive regimen prolongs In vivo persistence of gene-modified autologous T cells in a nonhuman primate model.

Authors:  C Berger; M L Huang; M Gough; P D Greenberg; S R Riddell; H P Kiem
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

2.  Implication of interfering antibody formation and apoptosis as two different mechanisms leading to variable duration of adenovirus-mediated transgene expression in immune-competent mice.

Authors:  D B Schowalter; C L Himeda; B L Winther; C B Wilson; M A Kay
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

3.  E1A and E1B proteins inhibit inflammation induced by adenovirus.

Authors:  Jerome Schaack; Michael L Bennett; Jeff D Colbert; Andres Vazquez Torres; Gerald H Clayton; David Ornelles; John Moorhead
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-19       Impact factor: 11.205

4.  A novel hybrid adenoretroviral vector with more extensive E3 deletion extends transgene expression in submandibular glands.

Authors:  Changyu Zheng; Ana P Cotrim; Nikolay Nikolov; Fumi Mineshiba; William Swaim; Bruce J Baum
Journal:  Hum Gene Ther Methods       Date:  2012-07-20       Impact factor: 2.396

5.  Adenovirus-mediated gene expression in vivo is enhanced by the antiapoptotic bcl-2 gene.

Authors:  G Bilbao; J L Contreras; H G Zhang; M J Pike; K Overturf; G Mikheeva; V Krasnykh; D T Curiel
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

Review 6.  Immunomodulatory functions encoded by the E3 transcription unit of adenoviruses.

Authors:  H G Burgert; J H Blusch
Journal:  Virus Genes       Date:  2000       Impact factor: 2.198

7.  A trial of somatic gene targeting in vivo with an adenovirus vector.

Authors:  Asami Ino; Yasuhiro Naito; Hiroyuki Mizuguchi; Naofumi Handa; Takao Hayakawa; Ichizo Kobayashi
Journal:  Genet Vaccines Ther       Date:  2005-10-12

Review 8.  The evolution of adenoviral vectors through genetic and chemical surface modifications.

Authors:  Cristian Capasso; Mariangela Garofalo; Mari Hirvinen; Vincenzo Cerullo
Journal:  Viruses       Date:  2014-02-17       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.